Therefore, NF-kB has increasingly become the focus of interest, outlining it as a potential therapeutic target in COPD treatment, and moreover, in the context of COVID-19 pneumonia (88). This evidence concerns the gene NFKB1 and chronic obstructive pulmonary disease.